

**“Optimising the management of Atrial Fibrillation (AF) through a pharmacist-led approach aligned to national policy which supports restoration and recovery of services through COVID-19 (C19)”**

**“Termination Statement of Joint Working Project”**

Bristol Myers Squibb (BMS) on behalf of BMS-Pfizer Alliance and Tower Family Healthcare entered into an agreement to deliver a “Optimising the management of Atrial Fibrillation (AF) through a pharmacist-led approach aligned to national policy which supports restoration and recovery of services through COVID-19 (C19)” collaborative working project.

Due to organisational changes within BMS and unforeseen circumstances within Tower Family Healthcare, the parties have agreed that the project objectives could no longer be met. The collaborative working agreement terminated in May 2023.

The project originally commenced in May 2021 and was terminated in May 2023.

END